{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:48:55Z","timestamp":1788835735605,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/MOH\/000627"],"award-info":[{"award-number":["NMRC\/MOH\/000627"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.05.029","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T02:21:10Z","timestamp":1654222870000},"page":"65-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5538","authenticated-orcid":false,"given":"Aaron Shengting","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-2929","authenticated-orcid":false,"given":"Ainsley Ryan Yan Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9773-411X","authenticated-orcid":false,"given":"Ryan Yong Kiat","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-8986","authenticated-orcid":false,"given":"Lauren","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7778-0752","authenticated-orcid":false,"given":"Astha","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3351-5719","authenticated-orcid":false,"given":"Albert","family":"Grinshpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Herishanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Benjamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Tadmor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-2672","authenticated-orcid":false,"given":"Rachna T.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-9337","authenticated-orcid":false,"given":"Bonnie J.","family":"LaFleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepta","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Tey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Yi Ann","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-1368","authenticated-orcid":false,"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda Xinwei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2022.05.029_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: what we know so far","volume":"72","author":"Fung","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ejca.2022.05.029_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jinf.2021.01.022","article-title":"COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients","volume":"82","author":"Belsky","year":"2021","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.ejca.2022.05.029_bib3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.dsx.2020.07.037","article-title":"Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis","volume":"14","author":"Salunke","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"9","key":"10.1016\/j.ejca.2022.05.029_bib4","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cncr.33386","article-title":"Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies","volume":"127","author":"Desai","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.05.029_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies","volume":"139","author":"Saini","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.05.029_bib6","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ejca.2022.05.029_bib7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.seminoncol.2015.05.007","article-title":"Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy","volume":"42","author":"Wargo","year":"2015","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.05.029_bib8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00262-016-1810-0","article-title":"High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy","volume":"65","author":"Kalathil","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.ejca.2022.05.029_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/NNR.0b013e31818fcecd","article-title":"Significant impairment in immune recovery after cancer treatment","volume":"58","author":"Kang","year":"2009","journal-title":"Nurs Res"},{"key":"10.1016\/j.ejca.2022.05.029_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis","volume":"114","author":"Zheng","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.ejca.2022.05.029_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5694\/mja2.51182","article-title":"Effectiveness of COVID-19 vaccines: findings from real world studies","volume":"215","author":"Henry","year":"2021","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.ejca.2022.05.029_bib12","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1080\/13696998.2021.1965732","article-title":"Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis","volume":"24","author":"Padula","year":"2021","journal-title":"J Med Econ"},{"issue":"8","key":"10.1016\/j.ejca.2022.05.029_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12032-021-01540-8","article-title":"Vaccination of cancer patients against COVID-19: towards the end of a dilemma","volume":"38","author":"Mandal","year":"2021","journal-title":"Med Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2022.05.029_bib14","article-title":"COVID-19 vaccine safety in cancer patients: a single centre experience","volume":"13","author":"So","year":"2021","journal-title":"Cancers Basel"},{"key":"10.1016\/j.ejca.2022.05.029_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2022.05.029_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","article-title":"Seroconversion rate after vaccination against COVID-19 in patients with cancer\u2014a systematic review","volume":"33","author":"Corti","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.05.029_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ejca.2022.05.029_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2022.05.029_bib19","doi-asserted-by":"crossref","unstructured":"Fendler A, Shepherd STC, Au L, et\u00a0al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. Published online December 29, 2021:S1535\u20136108(21)00666-8. doi:10.1016\/j.ccell.2021.12.013.","DOI":"10.1016\/j.ccell.2021.12.013"},{"key":"10.1016\/j.ejca.2022.05.029_bib20","doi-asserted-by":"crossref","unstructured":"Fenioux C, Teixeira L, Fourati S, et\u00a0al. SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. Published online January 7, 2022. doi:10.1001\/jamaoncol.2021.7777.","DOI":"10.1001\/jamaoncol.2021.7777"},{"key":"10.1016\/j.ejca.2022.05.029_bib21","doi-asserted-by":"crossref","unstructured":"Gounant V, Ferr\u00e9 VM, Soussi G, et\u00a0al. Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. Published online November 16, 2021. doi:10.1016\/j.jtho.2021.10.015.","DOI":"10.1016\/j.jtho.2021.10.015"},{"issue":"10","key":"10.1016\/j.ejca.2022.05.029_bib22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.05.029_bib23","doi-asserted-by":"crossref","unstructured":"Herishanu Y, Rahav G, Levi S, et\u00a0al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard two-dose vaccination. Blood. Published online December 3, 2021. doi:10.1182\/blood.2021014085.","DOI":"10.1182\/blood.2021014085"},{"key":"10.1016\/j.ejca.2022.05.029_bib24","doi-asserted-by":"crossref","unstructured":"Konishi Y, Sklavenitis-Pistofidis R, Yue H, et\u00a0al. Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia. Cancer Cell. Published online December 9, 2021. doi:10.1016\/j.ccell.2021.12.003.","DOI":"10.1016\/j.ccell.2021.12.003"},{"issue":"10","key":"10.1016\/j.ejca.2022.05.029_bib25","article-title":"Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia","volume":"9","author":"Marlet","year":"2021","journal-title":"Vaccines Basel"},{"issue":"1","key":"10.1016\/j.ejca.2022.05.029_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccell.2021.12.002","article-title":"Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer","volume":"40","author":"Naranbhai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.05.029_bib27","doi-asserted-by":"crossref","unstructured":"Re D, Seitz-Polski B, Carles M, et\u00a0al. Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies. medRxiv. Published online 2021:2021.07.18.21260669. doi:10.1101\/2021.07.18.21260669.","DOI":"10.1101\/2021.07.18.21260669"},{"issue":"10","key":"10.1016\/j.ejca.2022.05.029_bib28","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1016\/S2352-3026(21)00274-X","article-title":"Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT","volume":"8","author":"Redjoul","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2022.05.029_bib29","doi-asserted-by":"crossref","unstructured":"Reimann P, Ulmer H, Mutschlechner B, et\u00a0al. Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response. Br J Haematol. Published online December 6, 2021. doi:10.1111\/bjh.17982.","DOI":"10.1111\/bjh.17982"},{"key":"10.1016\/j.ejca.2022.05.029_bib30","doi-asserted-by":"crossref","unstructured":"Rottenberg Y, Grinshpun A, Ben-Dov IZ, Oiknine Djian E, Wolf DG, Kadouri L. Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol. Published online November 23, 2021. doi:10.1001\/jamaoncol.2021.6764.","DOI":"10.1001\/jamaoncol.2021.6764"},{"key":"10.1016\/j.ejca.2022.05.029_bib31","doi-asserted-by":"crossref","unstructured":"Shapiro LC, Thakkar A, Campbell ST, et\u00a0al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. Published online November 16, 2021. doi:10.1016\/j.ccell.2021.11.006.","DOI":"10.1016\/j.ccell.2021.11.006"},{"issue":"11","key":"10.1016\/j.ejca.2022.05.029_bib32","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.05.029_bib33","doi-asserted-by":"crossref","unstructured":"Zeng C, Evans JP, Chakravarthy K, et\u00a0al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. Published online December 30, 2021:S1535\u20136108(21)00688-7. doi:10.1016\/j.ccell.2021.12.014.","DOI":"10.1101\/2021.12.28.21268398"},{"key":"10.1016\/j.ejca.2022.05.029_bib34","doi-asserted-by":"crossref","unstructured":"Saiag E, Grupper A, Avivi I, et\u00a0al. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. Clin Microbiol Infect. Published online February 18, 2022. doi:10.1016\/j.cmi.2022.02.002.","DOI":"10.1016\/j.cmi.2022.02.002"},{"issue":"4","key":"10.1016\/j.ejca.2022.05.029_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2022.02.011","article-title":"Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination","volume":"40","author":"Ehmsen","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.05.029_bib36","doi-asserted-by":"crossref","unstructured":"Einarsdottir S, Martner A, Nicklasson M, et\u00a0al. Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation. Haematologica. Published online March 3, 2022. doi:10.3324\/haematol.2021.280494.","DOI":"10.3324\/haematol.2021.280494"},{"issue":"4","key":"10.1016\/j.ejca.2022.05.029_bib37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccell.2022.02.005","article-title":"Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients","volume":"40","author":"Canti","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ejca.2022.05.029_bib38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2022.02.010","article-title":"Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients","volume":"40","author":"Abid","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.05.029_bib39","doi-asserted-by":"crossref","unstructured":"\u0160u\u0161ol O, H\u00e1jkov\u00e1 B, Zelen\u00e1 H, H\u00e1jek R. Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. Br J Haematol. Published online January 25, 2022. doi:10.1111\/bjh.18073.","DOI":"10.1111\/bjh.18073"},{"issue":"7821","key":"10.1016\/j.ejca.2022.05.029_bib40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejca.2022.05.029_bib41","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/2159-8290.CD-20-0941","article-title":"Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer consortium (CCC19) cohort study","volume":"10","author":"Rivera","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejca.2022.05.029_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cid\/ciaa1079","article-title":"Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)?","volume":"72","author":"Chamilos","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"10","key":"10.1016\/j.ejca.2022.05.029_bib43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2022.05.029_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-021-01046-w","article-title":"COVID-19 vaccines for patients with cancer: benefits likely outweigh risks","volume":"14","author":"Hwang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2022.05.029_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2021.09.030","article-title":"Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment","volume":"159","author":"Buttiron Webber","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.05.029_bib46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1078\/0171-2985-00200","article-title":"Effective B cell depletion with rituximab in the treatment of autoimmune diseases","volume":"206","author":"Kneitz","year":"2002","journal-title":"Immunobiology"},{"issue":"12","key":"10.1016\/j.ejca.2022.05.029_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.ejca.2022.05.029_bib48","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-guideline of the infectious diseases working party (AGIHO) of the German society for hematology and medical Oncology (DGHO)","volume":"29","author":"Rieger","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.05.029_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"12","key":"10.1016\/j.ejca.2022.05.029_bib50","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","article-title":"High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study","volume":"40","author":"Loarce-Martos","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ejca.2022.05.029_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02147","article-title":"What's sex got to do with COVID-19? Gender-based differences in the host immune response to coronaviruses","volume":"11","author":"Gadi","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2022.05.029_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0165-5728(00)00296-4","article-title":"Cytokines and hormones as possible links between and immunosenescence","volume":"109","author":"Straub","year":"2000","journal-title":"J Neuroimmunol"},{"issue":"8","key":"10.1016\/j.ejca.2022.05.029_bib53","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ejca.2022.05.029_bib54","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/annonc\/mdq728","article-title":"Response to influenza virus vaccination during chemotherapy in patients with breast cancer","volume":"22","author":"Meerveld-Eggink","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.05.029_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncr.30468","article-title":"Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles","volume":"123","author":"Keam","year":"2017","journal-title":"Cancer"},{"issue":"52","key":"10.1016\/j.ejca.2022.05.029_bib56","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1016\/j.vaccine.2013.10.053","article-title":"Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours","volume":"31","author":"Wumkes","year":"2013","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.ejca.2022.05.029_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11864-021-00903-7","article-title":"Cancer or COVID-19? A review of recommendations for COVID-19 vaccination in cancer patients","volume":"22","author":"Gundavda","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.05.029_bib58","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/vaccines10050668","article-title":"Booster COVID-19 vaccines for immune-mediated inflammatory disease patients: a systematic review and meta-analysis of efficacy and safety","volume":"10","author":"Lee","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.ejca.2022.05.029_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/vaccines10010095","article-title":"Efficacy and safety of third dose of the COVID-19 vaccine among solid organ transplant recipients: a systemic review and meta-analysis","volume":"10","author":"Efros","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ejca.2022.05.029_bib60","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: a systematic review and meta-analysis","author":"Lee","year":"2021","journal-title":"medRxiv"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:38Z","timestamp":1760733398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":60,"alternative-id":["S0959804922003082"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}